Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Clin Cancer Res. 2012 Jan 23;18(7):2039–2047. doi: 10.1158/1078-0432.CCR-11-1823

Table 2.

Frequency and duration of objective tumor responses.

Protocol 1
Ipi+ gp100		 Protocol 2
Ipi + IL-2		 Protocol 3
Ipi (DE) ± gp100
No. of pts. (%)
(N = 56)		 No. of pts. (%)
(N = 36)		 No. of pts. (%)
(N = 85)
Initial Report PR 5 (9%) 5 (14%) 5 (out of 46; 11%)
CR 2 (4%) 3 (8%) 0 (0%)
Total OR 7 (13%) 8 (22%) 5 (out of 46; 11%)
Current Status PR 3 (6%) 3 (8%) 12 (14%)
CR 4 (7%) 6 (17%) 5 (6%)
Total OR 7 (13%) 9 (25%) 17 (20%)
Response Duration (months) PR 42, 5, 4 11, 11, 5 71+, 68, 66+, 56+, 25, 15, 11, 10, 9, 7, 6, 5
CR 99+, 94+, 94+, 88+ 89+, 86+, 83+, 83+, 79+, 76+ 76+, 74+, 62+ 54+, 42

Abbreviations: CR, complete response; DE, intra-patient dose escalation of ipilimumab; gp100, gp100:209–217(210M) and gp100:280–288(288V) peptides; IL-2, interleukin-2; ipi, ipilimumab; OR, objective response; PR, partial response.